Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT07213206 | CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer(Cinderella) | not yet recruiting | Phase 3 | 1,500 | Fudan UniversityOTHER | 0 | Oct 8, 2025 |
| clinicaltrials |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy(ASCENT-07) | active not recruiting | Phase 3 | 654 | Gilead SciencesINDUSTRY | 28 | Oct 3, 2025 | clinicaltrials |
| NCT07166042 | Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies(Med-RT BG) | recruiting | Phase 3 | 34 | University of UtahOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07190443 | Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)(AURA) | recruiting | Phase 3 | 290 | Japanese Foundation for Cancer ResearchOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | recruiting | Phase 3 | 400 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04254263 | Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer(ATP) | recruiting | Phase 3 | 316 | RenJi HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05063786 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)(ALPHABET) | active not recruiting | Phase 3 | 27 | Spanish Breast Cancer Research GroupOTHER | 6 | Sep 8, 2025 | clinicaltrials |
| NCT04134598 | ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer(EUROPA) | active not recruiting | Phase 3 | 926 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05744687 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | recruiting | Phase 2 / Phase 3 | 374 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07008976 | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 246 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05802225 | Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer(PREFER) | active not recruiting | Phase 3 | 398 | BiocadINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05257395 | A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | active not recruiting | Phase 3 | 397 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease(ZEST) | active not recruiting | Phase 3 | 40 | GlaxoSmithKlineINDUSTRY | 27 | Jul 16, 2025 | clinicaltrials |
| NCT07066280 | Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer | recruiting | Phase 3 | 326 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02455141 | Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer(TCTN) | active not recruiting | Phase 3 | 786 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
| NCT06835400 | Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | not yet recruiting | Phase 3 | 340 | Health Hope PharmaINDUSTRY | 0 | Jul 11, 2025 | clinicaltrials |
| NCT07057427 | Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 812 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06839001 | CRYoablation for Small Tumors As Local Treatment - SIX Trial(CRYSTAL - SIX) | recruiting | Phase 3 | 750 | Hospital do CoracaoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07003074 | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 642 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06434077 | Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer | not yet recruiting | Phase 3 | 60 | S.LAB (SOLOWAYS)OTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06383767 | A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | recruiting | Phase 3 | 378 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | active not recruiting | Phase 3 | 11,000 | University College, LondonOTHER | 2 | Jun 10, 2025 | clinicaltrials |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | active not recruiting | Phase 3 | 900 | Shanghai Henlius BiotechINDUSTRY | 4 | Jun 10, 2025 | clinicaltrials |
| NCT07005557 | Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer(SENIOR) | not yet recruiting | Phase 3 | 1,244 | Fudan UniversityOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT05838066 | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | recruiting | Phase 3 | 880 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT06996093 | Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor | not yet recruiting | Phase 3 | 2,508 | Fudan UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06915857 | Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position | recruiting | Phase 3 | 276 | Sunnybrook Health Sciences CentreOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06977893 | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) | recruiting | Phase 3 | 194 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | active not recruiting | Phase 3 | 575 | OBI Pharma, IncINDUSTRY | 13 | May 9, 2025 | clinicaltrials |
| NCT04261244 | NeoRad Breast Cancer Study(NeoRad) | recruiting | Phase 3 | 1,826 | Bielefeld UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06643585 | A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse(SURVIVE HERoes) | recruiting | Phase 3 | 180 | Prof. Wolfgang JanniOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06947330 | Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy(FMASUMD66/2025) | recruiting | Phase 3 | 100 | Kholoud UsamaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06313983 | A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | recruiting | Phase 3 | 339 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06223698 | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer(SWE-Switch) | not yet recruiting | Phase 3 | 3,832 | Region Örebro CountyOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer(Breast53) | recruiting | Phase 2 / Phase 3 | 45 | University of VirginiaOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06929325 | Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors | not yet recruiting | Phase 3 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06926543 | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy(CONCERT) | recruiting | Phase 3 | 858 | Dr. Tabassum WadasadawalaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 8, 2025source: clinicaltrials